SecBot SecBot

ALMS

ALUMIS INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001847367 Biotech & Drug Discovery
$6.53 −0.25 (−3.69%)
Oct 26 4:00 PM ET · prev $6.78
Market cap
$882.7M
Small cap
Consensus
Buy
88% Buy or better · 16 analysts
Median target
$28.00
+329% · range $15.00–46.00
Next earnings
Nov 12
in 17 days · EPS est. −$0.75
1 year
+35.8%
from $4.81 · Oct 27
30 days
−8.8%
from $7.16
52-week range
$4.55–30.30
−78% from high · low Nov 4
Avg volume 20D
1.91M
shares / day
Short interest
10.30M
≈8.0% of shares · +63.5%
Days to cover
3.6
at average volume
Insider net
+$6.7M
1 buyer · 7 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 3 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/6 ·Next Earnings date, Nov 12, 2026
Strongest MIXED Alumis reported topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe SLE…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $8.3M at an average $10.78. 7 insiders sold $1.5M. Price is 39% below their cost.

  • InstitutionsMIXED

    Q2 2026: 25 added (1 new), 17 trimmed or exited. Largest new: Woodline Partners $13.7M.

  • AnalystsBULLISH

    14 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.724 → −$0.750 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersBUILDING

    Short interest +63.5% to 10.30M shares. 3.6 days to cover, ≈8.0% of shares.

  • TrendDOWNTREND

    42% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$13.7M
in new stakes
FundMoveSharesValue
FMR LLCDOUBLED6,769,170$190.5M
PRICE T ROWE ASSOCIATES INC /MD/ADD5,199,838$146.3M
D. E. Shaw & Co., Inc.ADD968,234$27.2M
UBS Group AGTRIM951,796$26.8M
VANGUARD PORTFOLIO MANAGEMENT LLCADD921,211$25.9M
NORTHERN TRUST CORPADD723,849$20.4M
Woodline Partners LPNEW486,052$13.7M
CITIGROUP INCDOUBLED385,400$10.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 88% rate it Buy or better
Strong Buy7Buy7Hold2Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +329%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 3, 2026Guggenheim
DOWNGRADE
DOWNGRADENeutral
Sep 2, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Sep 2, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Sep 2, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Sep 2, 2026HC Wainwright & Co.
UPGRADE
UPGRADEBuy
Aug 14, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral

Insider ledger

Form 4
$8.3M
bought · 1 insider
$1.5M
sold · 7 insiders
−39.4%
vs their $10.78 cost
DateInsiderTypeValue
Sep 8, 2026
AKKARAJU SRINIVAS
Director
SELL$507.0K
Sep 8, 2026
AKKARAJU SRINIVAS
Director
SELL$507.0K
Sep 8, 2026
AKKARAJU SRINIVAS
Director
BUY$2.9M
Sep 8, 2026
AKKARAJU SRINIVAS
Director
BUY$2.9M
Sep 4, 2026
AKKARAJU SRINIVAS
Director
BUY$2.5M
Aug 3, 2026
Pangali Sanam
Chief Legal Officer
SELL$36.0K
Aug 3, 2026
Goldstein David M
Chief Scientific Officer
SELL$68.5K
Aug 3, 2026
Schroer John R.
Chief Financial Officer
SELL$86.5K

Earnings setup

Estimates
Nov 12
reports in 17 days
−$0.75
EPS estimate, this quarter
−4%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.75-$0.80–-$0.70+0.0%$1.7M
Next Q-$0.72-$0.78–-$0.64+0.0%$1.7M
Current FY-$3.32-$3.44–-$3.23-1.8%$6.3M
Next FY-$2.87-$3.09–-$2.62+0.0%$24.3M

Short side

FINRA· Sep 30, 2026
10,295,705
shares short
+63.5%
vs prior settlement
3.6
days to cover
≈8.0%
of shares outstanding
Trading halts
Sep 1, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Short interest report
Short Interest: ALMS up 63% to 10.3M shares
Settlement 2026-09-30 | Days to cover: 3.59 | ≈7.95% of shares outstanding (est.)
Sep 9, 2026 SEC
Director Srinivas Akkaraju made a single open-market purchase of 220,070 shares of ALMS for $2.46M on September 4…
INSIDER-BUY — Impact 5/10
Sep 8, 2026 Insider
AKKARAJU SRINIVAS sold 48,066 shares
Director @ $10.55 ($507.0K)
Sep 8, 2026 Insider
AKKARAJU SRINIVAS sold 48,065 shares
Director @ $10.55 ($507.0K)
Sep 8, 2026 Insider
AKKARAJU SRINIVAS bought 273,291 shares
Director @ $10.63 ($2.9M)
Sep 1, 2026 SEC
Alumis reported topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe SLE. The trial…
8-K — Impact 6/10
Aug 15, 2026 SEC
A strong institutional cluster of 9 buyers accumulated $186.9M in ALMS during Q2 2026, led by Fidelity doubling its…
INST-CLUSTER — Impact 6/10
Jun 30, 2026 Inst.
FMR LLC — DOUBLED
6,769,170 shares ($190.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
ALMS Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Sep 30, 2026
Short interest
Short Interest: ALMS up 63% to 10.3M shares
Settlement 2026-09-30 | Days to cover: 3.59 | ≈7.95% of shares outstanding (est.)
Sep 4, 2026
Press release
Alumis to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing…
Sep 1, 2026
Trading halt
Halt Resumed: ALMS — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-01T11:25:00.000Z | Resumed 2026-09-01T12:50:00.000Z
Sep 1, 2026
Press release
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
Sep 1, 2026
Trading halt
Trading Halt: ALMS — T2 (News Released)
Alumis Inc. Common Stock | Market: NASDAQ | Code: T2 — News Released

SecBot reports

9 filings · 2 press releases · 3 bullish · 0 bearish · 1 mixed · 5 neutral
All ALMS filing & press-release reports (11)